ZA200403685B - Cannabinoid receptor ligands. - Google Patents

Cannabinoid receptor ligands. Download PDF

Info

Publication number: ZA200403685B
Authority: ZA; South Africa
Prior art keywords: compound; composition; alkyl; group; substance
Prior art date: 2001-11-14

Application number

ZA200403685A

Other languages

English (en)

Inventor

Richard J Friary

Bandarpalle B Shankar

Guowel Zhou

Neng-Yang Shih

Lei Chen

Joseph A Kozlowski

Michael K C Wong

Brian J Lavey

Ling Tong

Youheng Shu

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-14

Filing date

2004-05-13

Publication date

2005-05-23

2004-05-13 Application filed by Schering Corp filed Critical Schering Corp

2005-05-23 Publication of ZA200403685B publication Critical patent/ZA200403685B/en

Links

102000018208 Cannabinoid Receptor Human genes 0.000 title description 7
108050007331 Cannabinoid receptor Proteins 0.000 title description 7
239000003446 ligand Substances 0.000 title description 5
150000001875 compounds Chemical class 0.000 claims description 165
125000000217 alkyl group Chemical group 0.000 claims description 99
125000000753 cycloalkyl group Chemical group 0.000 claims description 68
125000001188 haloalkyl group Chemical group 0.000 claims description 67
125000003118 aryl group Chemical group 0.000 claims description 50
125000001072 heteroaryl group Chemical group 0.000 claims description 44
125000003545 alkoxy group Chemical group 0.000 claims description 43
229910052736 halogen Inorganic materials 0.000 claims description 40
150000002367 halogens Chemical class 0.000 claims description 40
125000004438 haloalkoxy group Chemical group 0.000 claims description 29
-1 N(R")o Chemical group 0.000 claims description 18
229910052739 hydrogen Inorganic materials 0.000 claims description 17
201000006417 multiple sclerosis Diseases 0.000 claims description 17
206010039073 rheumatoid arthritis Diseases 0.000 claims description 17
201000004681 Psoriasis Diseases 0.000 claims description 16
241000124008 Mammalia Species 0.000 claims description 15
125000001041 indolyl group Chemical group 0.000 claims description 15
125000004356 hydroxy functional group Chemical group O* 0.000 claims description 12
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
125000004076 pyridyl group Chemical group 0.000 claims description 11
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 10
208000036284 Rhinitis seasonal Diseases 0.000 claims description 10
201000010105 allergic rhinitis Diseases 0.000 claims description 10
208000017022 seasonal allergic rhinitis Diseases 0.000 claims description 10
208000006673 asthma Diseases 0.000 claims description 9
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
230000002519 immonomodulatory effect Effects 0.000 claims description 7
125000004122 cyclic group Chemical group 0.000 claims description 6
125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 6
201000010099 disease Diseases 0.000 claims description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
125000003373 pyrazinyl group Chemical group 0.000 claims description 6
201000006474 Brain Ischemia Diseases 0.000 claims description 5
206010008120 Cerebral ischaemia Diseases 0.000 claims description 5
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
208000001132 Osteoporosis Diseases 0.000 claims description 5
206010063897 Renal ischaemia Diseases 0.000 claims description 5
208000006011 Stroke Diseases 0.000 claims description 5
206010052779 Transplant rejections Diseases 0.000 claims description 5
206010008118 cerebral infarction Diseases 0.000 claims description 5
229910052801 chlorine Inorganic materials 0.000 claims description 5
206010012601 diabetes mellitus Diseases 0.000 claims description 5
229910052731 fluorine Inorganic materials 0.000 claims description 5
125000002541 furyl group Chemical group 0.000 claims description 5
125000001624 naphthyl group Chemical group 0.000 claims description 5
201000008383 nephritis Diseases 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 5
125000002098 pyridazinyl group Chemical group 0.000 claims description 5
125000000714 pyrimidinyl group Chemical group 0.000 claims description 5
125000000168 pyrrolyl group Chemical group 0.000 claims description 5
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 5
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 5
125000000335 thiazolyl group Chemical group 0.000 claims description 5
125000001544 thienyl group Chemical group 0.000 claims description 5
208000000884 Airway Obstruction Diseases 0.000 claims description 4
206010006458 Bronchitis chronic Diseases 0.000 claims description 4
208000011231 Crohn disease Diseases 0.000 claims description 4
208000010412 Glaucoma Diseases 0.000 claims description 4
206010020751 Hypersensitivity Diseases 0.000 claims description 4
208000026935 allergic disease Diseases 0.000 claims description 4
230000007815 allergy Effects 0.000 claims description 4
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
206010006451 bronchitis Diseases 0.000 claims description 4
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
208000007451 chronic bronchitis Diseases 0.000 claims description 4
125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 4
125000005956 isoquinolyl group Chemical group 0.000 claims description 4
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
230000002441 reversible effect Effects 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims description 4
201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
206010012438 Dermatitis atopic Diseases 0.000 claims description 3
206010018364 Glomerulonephritis Diseases 0.000 claims description 3
201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 3
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
206010028980 Neoplasm Diseases 0.000 claims description 3
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
208000017442 Retinal disease Diseases 0.000 claims description 3
206010040047 Sepsis Diseases 0.000 claims description 3
208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 3
206010047115 Vasculitis Diseases 0.000 claims description 3
208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 3
201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 3
201000008937 atopic dermatitis Diseases 0.000 claims description 3
206010006475 bronchopulmonary dysplasia Diseases 0.000 claims description 3
201000011510 cancer Diseases 0.000 claims description 3
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 3
201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 3
208000006454 hepatitis Diseases 0.000 claims description 3
231100000283 hepatitis Toxicity 0.000 claims description 3
208000027866 inflammatory disease Diseases 0.000 claims description 3
208000036971 interstitial lung disease 2 Diseases 0.000 claims description 3
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
201000005962 mycosis fungoides Diseases 0.000 claims description 3
208000010125 myocardial infarction Diseases 0.000 claims description 3
208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
125000005493 quinolyl group Chemical group 0.000 claims description 3
201000000306 sarcoidosis Diseases 0.000 claims description 3
230000035939 shock Effects 0.000 claims description 3
239000012453 solvate Substances 0.000 claims description 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 2
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
229910052794 bromium Inorganic materials 0.000 claims description 2
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
239000000203 mixture Substances 0.000 claims 70
239000000126 substance Substances 0.000 claims 55
238000000034 method Methods 0.000 claims 42
230000001506 immunosuppresive effect Effects 0.000 claims 33
150000003431 steroids Chemical class 0.000 claims 33
229940111134 coxibs Drugs 0.000 claims 17
239000003260 cyclooxygenase 1 inhibitor Substances 0.000 claims 17
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 17
239000003814 drug Substances 0.000 claims 15
238000004519 manufacturing process Methods 0.000 claims 15
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 12
229930105110 Cyclosporin A Natural products 0.000 claims 12
108010036949 Cyclosporine Proteins 0.000 claims 12
108010008165 Etanercept Proteins 0.000 claims 12
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 12
229960001265 ciclosporin Drugs 0.000 claims 12
229930182912 cyclosporin Natural products 0.000 claims 12
229940073621 enbrel Drugs 0.000 claims 12
VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 12
229960000681 leflunomide Drugs 0.000 claims 12
229940116176 remicade Drugs 0.000 claims 12
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 12
229960001940 sulfasalazine Drugs 0.000 claims 12
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 12
108010072051 Glatiramer Acetate Proteins 0.000 claims 11
108010005716 Interferon beta-1a Proteins 0.000 claims 11
108010005714 Interferon beta-1b Proteins 0.000 claims 11
229940003504 avonex Drugs 0.000 claims 11
229940021459 betaseron Drugs 0.000 claims 11
229940038717 copaxone Drugs 0.000 claims 11
229920000728 polyester Polymers 0.000 claims 10
239000000938 histamine H1 antagonist Substances 0.000 claims 7
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 6
229940047495 celebrex Drugs 0.000 claims 6
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical group C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 6
229940065410 feldene Drugs 0.000 claims 6
229960000485 methotrexate Drugs 0.000 claims 6
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical group OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 6
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 6
229940087652 vioxx Drugs 0.000 claims 6
108060008682 Tumor Necrosis Factor Proteins 0.000 claims 5
102100040247 Tumor necrosis factor Human genes 0.000 claims 5
201000009961 allergic asthma Diseases 0.000 claims 5
239000003937 drug carrier Substances 0.000 claims 4
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
208000023504 respiratory system disease Diseases 0.000 claims 2
ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims 1
JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 claims 1
239000008186 active pharmaceutical agent Substances 0.000 claims 1
229940008201 allegra Drugs 0.000 claims 1
239000005557 antagonist Substances 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 claims 1
229940119122 clarinex Drugs 0.000 claims 1
229940088529 claritin Drugs 0.000 claims 1
125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 1
RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 1
JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims 1
206010025135 lupus erythematosus Diseases 0.000 claims 1
238000001320 near-infrared absorption spectroscopy Methods 0.000 claims 1
230000009885 systemic effect Effects 0.000 claims 1
229940036139 zyrtec Drugs 0.000 claims 1
125000004432 carbon atom Chemical group C* 0.000 description 12
125000000304 alkynyl group Chemical group 0.000 description 6
125000006413 ring segment Chemical group 0.000 description 6
125000003710 aryl alkyl group Chemical group 0.000 description 5
125000001424 substituent group Chemical group 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
125000002877 alkyl aryl group Chemical group 0.000 description 4
102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 3
108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
230000003110 anti-inflammatory effect Effects 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 2
108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
125000002947 alkylene group Chemical group 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
125000003226 pyrazolyl group Chemical group 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
150000001204 N-oxides Chemical class 0.000 description 1
208000018569 Respiratory Tract disease Diseases 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
241000534944 Thia Species 0.000 description 1
125000004414 alkyl thio group Chemical group 0.000 description 1
IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
125000005513 benzoazaindolyl group Chemical group 0.000 description 1
125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229930003827 cannabinoid Natural products 0.000 description 1
239000003557 cannabinoid Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
208000023819 chronic asthma Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
125000003838 furazanyl group Chemical group 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
125000005945 imidazopyridyl group Chemical group 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
125000000547 substituted alkyl group Chemical group 0.000 description 1
125000004426 substituted alkynyl group Chemical group 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
125000003944 tolyl group Chemical group 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Neurology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Transplantation (AREA)
Emergency Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

ZA200403685A 2001-11-14 2004-05-13 Cannabinoid receptor ligands. ZA200403685B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US33291101P	2001-11-14	2001-11-14

Publications (1)

Publication Number	Publication Date
ZA200403685B true ZA200403685B (en)	2005-05-23

Family

ID=23300394

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200403685A ZA200403685B (en)	2001-11-14	2004-05-13	Cannabinoid receptor ligands.

Country Status (20)

Country	Link
US (2)	US7071213B2 (pt)
EP (1)	EP1444203A1 (pt)
JP (2)	JP2005509032A (pt)
KR (1)	KR20050044417A (pt)
CN (2)	CN100567266C (pt)
AR (1)	AR037352A1 (pt)
BR (1)	BR0214164A (pt)
CA (1)	CA2466440A1 (pt)
EC (1)	ECSP045104A (pt)
HU (1)	HUP0401924A3 (pt)
IL (1)	IL161439A0 (pt)
MX (1)	MXPA04004674A (pt)
NO (1)	NO20042435L (pt)
NZ (1)	NZ532291A (pt)
PE (1)	PE20030720A1 (pt)
PL (1)	PL369952A1 (pt)
RU (1)	RU2004117907A (pt)
TW (1)	TW200302088A (pt)
WO (1)	WO2003042174A1 (pt)
ZA (1)	ZA200403685B (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7067539B2 (en)	2001-02-08	2006-06-27	Schering Corporation	Cannabinoid receptor ligands
US7507767B2 (en)	2001-02-08	2009-03-24	Schering Corporation	Cannabinoid receptor ligands
US7868204B2 (en) *	2001-09-14	2011-01-11	Methylgene Inc.	Inhibitors of histone deacetylase
US6897220B2 (en) *	2001-09-14	2005-05-24	Methylgene, Inc.	Inhibitors of histone deacetylase
KR20040048411A (ko) *	2001-09-14	2004-06-09	메틸진, 인크.	히스톤 데아세틸라아제의 억제제
JP2005509032A (ja)	2001-11-14	2005-04-07	シェーリング　コーポレイション	カンナビノイドレセプターリガンド
EP1314733A1 (en) *	2001-11-22	2003-05-28	Aventis Pharma Deutschland GmbH	Indole-2-carboxamides as factor Xa inhibitors
MXPA04012704A (es)	2002-06-19	2005-03-23	Schering Corp	Agonistas de los receptores canabinoides.
WO2004048322A1 (en)	2002-11-25	2004-06-10	Schering Corporation	Cannabinoid receptor ligands
MXPA05009771A (es) *	2003-03-14	2005-10-26	Ono Pharmaceutical Co	Derivados heterociclicos que contienen nitrogeno y medicamentos que los contienen como el ingrediente activo.
AR043633A1 (es)	2003-03-20	2005-08-03	Schering Corp	Ligandos de receptores de canabinoides
ATE413178T1 (de) *	2003-03-24	2008-11-15	Actimis Pharmaceuticals Inc	2-phenoxy- und 2-phenylsulfanyl-benzenesulfonamid derivate mit ccr3 antagonistischer aktivität zur behandlung von asthma und anderen entzündlichen oder immunologischen erkrankungen
US6916852B2 (en) *	2003-05-12	2005-07-12	University Of Tennessee Research Foundation	Method for regulation of microvascular tone
WO2004113320A1 (en) *	2003-05-20	2004-12-29	The University Of Tennessee Research Foundation	Cannabinoid derivatives, methods of making, and use thereof
JP4809228B2 (ja) *	2003-09-24	2011-11-09	メチルジーンインコーポレイテッド	ヒストンデアセチラーゼの阻害剤
PL1701940T3 (pl) *	2003-12-23	2008-11-28	H Lundbeck As	Pochodne 2-(1H-indolilosulfanylo)benzyloaminy jako SSRI
CN1980929A (zh) *	2004-02-24	2007-06-13	比奥阿克松医疗技术股份有限公司	4－取代哌啶衍生物
US7253204B2 (en) *	2004-03-26	2007-08-07	Methylgene Inc.	Inhibitors of histone deacetylase
WO2005097127A2 (en)	2004-04-02	2005-10-20	Merck & Co., Inc.	Method of treating men with metabolic and anthropometric disorders
EP1768667B1 (en) *	2004-06-22	2009-09-30	Schering Corporation	Cannabinoid receptor ligands
AR052308A1 (es) *	2004-07-16	2007-03-14	Lundbeck & Co As H	Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
FR2874012B1 (fr)	2004-08-09	2008-08-22	Sanofi Synthelabo	Derives de pyrrole, leur preparation et leur utlisation en therapeutique
SG146673A1 (en)	2004-09-13	2008-10-30	Ono Pharmaceutical Co	Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
KR20070058565A (ko) *	2004-09-30	2007-06-08	머크 앤드 캄파니 인코포레이티드	사이클로프로필 피페리딘 글리신 트랜스포터 억제제
US7517991B2 (en)	2004-10-12	2009-04-14	Bristol-Myers Squibb Company	N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7759339B2 (en) *	2005-03-31	2010-07-20	Takeda San Diego, Inc.	Hydroxysteroid dehydrogenase inhibitors
AR054393A1 (es) *	2005-06-17	2007-06-20	Lundbeck & Co As H	Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
US7629473B2 (en) *	2005-06-17	2009-12-08	H. Lundbeck A/S	2-(1H-indolylsulfanyl)-aryl amine derivatives
US20100222387A1 (en) *	2005-06-23	2010-09-02	Barrow James C	3-Fluoro-Piperidine T-Type Calcium Channel Antagonists
CN101212974A (zh) *	2005-06-29	2008-07-02	默克公司	4-氟-哌啶t-型钙通道拮抗剂
US7947714B2 (en) *	2005-10-28	2011-05-24	Merck, Sharp & Dohme Corp.	Piperidine glycine transporter inhibitors
GB0523609D0 (en) *	2005-11-19	2005-12-28	Vernalis R&D Ltd	Piperazine derivatives
JP2009525954A (ja) *	2006-01-13	2009-07-16	シェーリングコーポレイション	Ｃｂ１モジュレーターとしてのジアリールピペリジン
MX2008011414A (es) *	2006-03-10	2008-09-22	Ono Pharmaceutical Co	Derivado heterociclico nitrogenado y agente farmaceutico que comprende el derivado como ingrediente activo.
US8598168B2 (en) *	2006-04-07	2013-12-03	Methylgene Inc.	Inhibitors of histone deacetylase
MX2009002785A (es) *	2006-09-13	2009-03-30	Procter & Gamble	Metodos para el tratamiento de la colitis ulcerosa.
FR2907784B1 (fr) *	2006-10-27	2009-02-13	Sod Conseils Rech Applic	Derives phenyliques et leur utilisation comme medicament
EP2120938A4 (en) *	2006-12-20	2010-12-08	Merck Sharp & Dohme	IMIDAZOPYRIDINE ANALOGUE AS CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES
CA2685208C (en) *	2007-04-24	2014-04-08	Novelmed Therapeutics, Inc.	Methods and compositions of inhibiting complement and cellular activation with dextran sulfate
WO2010077624A1 (en)	2008-12-09	2010-07-08	Merck Sharp & Dohme Corp.	Biaryl carboxamides
US8809538B2 (en)	2009-01-12	2014-08-19	Array Biopharma Inc.	Piperidine-containing compounds and use thereof
MY162440A (en) *	2009-04-22	2017-06-15	Axikin Pharmaceuticals Inc	2,5-disubstituted arylsulfonamide ccr3 antagonists
US8258158B2 (en)	2009-09-11	2012-09-04	Hoffmann-La Roche Inc.	HSL inhibitors useful in the treatment of diabetes
GB201103419D0 (pt) *	2011-02-28	2011-04-13	Univ Aberdeen
US9636298B2 (en)	2014-01-17	2017-05-02	Methylgene Inc.	Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs
US10106525B2 (en)	2015-01-26	2018-10-23	BioAxone BioSciences, Inc.	Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10149856B2 (en)	2015-01-26	2018-12-11	BioAxone BioSciences, Inc.	Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10857157B2 (en)	2015-01-26	2020-12-08	BioAxone BioSciences, Inc.	Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US11198680B2 (en)	2016-12-21	2021-12-14	BioAxone BioSciences, Inc.	Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
WO2019014322A1 (en)	2017-07-11	2019-01-17	BioAxone BioSciences, Inc.	KINASE INHIBITORS FOR THE TREATMENT OF DISEASES
CN114867720B (zh)	2020-01-16	2024-10-22	浙江海正药业股份有限公司	杂芳基类衍生物及其制备方法和用途
US12018016B2 (en)	2021-08-18	2024-06-25	Amgen Inc.	Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors
MX2024002173A (es)	2021-08-18	2024-03-26	Chemocentryx Inc	Compuestos de arilsulfonilo como inhibidores de ccr6.

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3702324A (en) *	1970-06-24	1972-11-07	Stanford Research Inst	3,4,5-trimethoxybenzamides of substituted anilines and of alkylpiperidines
US4486965A (en) *	1982-05-14	1984-12-11	Nike, Inc.	Footwear with overlapping closure strap means
US4466965A (en)	1982-07-26	1984-08-21	American Hospital Supply Corporation	Phthalazine compounds, compositions and use
US4567184A (en)	1982-12-01	1986-01-28	Usv Pharmaceutical Corporation	Certain aryl or hetero-aryl derivatives of 1-hydroxy-pentane or 1-hydroxy-hexane which are useful for treating inflammation and allergies
NO174506B (no)	1984-10-30	1994-02-07	Usv Pharma Corp	Analogifremgangsmaate ved fremstilling av terapeutisk aktive forbindelser
US5064825A (en)	1989-06-01	1991-11-12	Merck & Co., Inc.	Angiotensin ii antagonists
EP0407217A1 (en)	1989-07-07	1991-01-09	Schering Corporation	Pharmaceutically active compounds
US5332820A (en)	1991-05-20	1994-07-26	E. I. Du Pont De Nemours And Company	Dibenzobicyclo(2.2.2) octane angiotensin II antagonists
US5506227A (en)	1992-04-13	1996-04-09	Merck Frosst Canada, Inc.	Pyridine-substituted benzyl alcohols as leukotriene antagonists
JPH0672979A (ja)	1992-06-08	1994-03-15	Hiroyoshi Hidaka	アミノベンジル誘導体
US5338753A (en)	1992-07-14	1994-08-16	Sumner H. Burstein	(3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
JP3254745B2 (ja)	1992-08-27	2002-02-12	住友化学工業株式会社	ジオール化合物およびその製造法
US5486525A (en)	1993-12-16	1996-01-23	Abbott Laboratories	Platelet activating factor antagonists: imidazopyridine indoles
FR2714057B1 (fr)	1993-12-17	1996-03-08	Sanofi Elf	Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
TW406075B (en) *	1994-12-13	2000-09-21	Upjohn Co	Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
IT1271266B (it)	1994-12-14	1997-05-27	Valle Francesco Della	Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
ATE197300T1 (de)	1995-02-02	2000-11-15	Smithkline Beecham Plc	Indolderivate als 5-ht rezeptorantagoniste
US5532237A (en)	1995-02-15	1996-07-02	Merck Frosst Canada, Inc.	Indole derivatives with affinity for the cannabinoid receptor
FR2735774B1 (fr)	1995-06-21	1997-09-12	Sanofi Sa	Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
AU715762B2 (en)	1995-07-21	2000-02-10	Nycomed Austria Gmbh	Derivatives of benzosulphonamides as inhibitors of the enzyme cyclooxygenase II
DE19533644A1 (de)	1995-09-12	1997-03-13	Nycomed Arzneimittel Gmbh	Neue Benzolsulfonamide
FR2742148B1 (fr)	1995-12-08	1999-10-22	Sanofi Sa	Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
EP0887340A4 (en)	1996-02-06	2000-03-29	Japan Tobacco Inc	CHEMICAL COMPOUNDS AND THEIR PHARMACEUTICAL USE
JP2001500864A (ja)	1996-09-13	2001-01-23	メルクエンドカンパニーインコーポレーテッド	トロンビン阻害物質
US6100259A (en)	1997-01-21	2000-08-08	Smithkline Beecham Corporation	Cannabinoid receptor modulators
ATA16597A (de)	1997-02-03	1998-04-15	Nycomed Austria Gmbh	Neue substituierte p-sulfonylaminobenzol- sulfonsäureamide
WO1998041519A1 (en)	1997-03-18	1998-09-24	Smithkline Beecham Corporation	Novel cannabinoid receptor agonists
CN1158278C (zh)	1997-10-24	2004-07-21	日产化学工业株式会社	氨磺酰基化合物和农业园艺用杀菌剂
WO1999026612A1 (en)	1997-11-21	1999-06-03	Smithkline Beecham Corporation	Novel cannabinoid receptor modulators
MY153569A (en)	1998-01-20	2015-02-27	Mitsubishi Tanabe Pharma Corp	Inhibitors of ?4 mediated cell adhesion
AU752005B2 (en)	1998-03-26	2002-09-05	Shionogi & Co., Ltd.	Indole derivatives with antiviral activity
HUP0102752A3 (en)	1998-07-28	2002-11-28	Smithkline Beecham Corp	Substituted anilide compounds
RU2264810C2 (ru)	1999-11-26	2005-11-27	Сионоги Энд Ко., Лтд.	Антагонист npy y5
EP1741713A3 (en)	1999-12-15	2009-09-09	Bristol-Myers Squibb Company	Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
CA2394639A1 (en)	1999-12-15	2001-06-21	Danny Peter Claude Mcgee	Salicylamides as serine protease and factor xa inhibitors
WO2001064642A2 (en)	2000-02-29	2001-09-07	Cor Therapeutics, Inc.	Benzamides and related inhibitors of factor xa
AU4398801A (en)	2000-03-22	2001-10-03	Banyu Pharmaceutical Co., Ltd.	Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors
AU2001253147A1 (en)	2000-04-03	2001-10-15	Phycogen, Inc.	Generation of combinatorial synthetic libraries and screening for proadhesins and nonadhesins
WO2001083460A1 (fr)	2000-04-28	2001-11-08	Tanabe Seiyaku Co., Ltd.	Composes cycliques
AU2001258771A1 (en)	2000-05-19	2001-11-26	Takeda Chemical Industries Ltd.	-secretase inhibitors
US6506901B2 (en) *	2000-07-17	2003-01-14	Wyeth	Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
US7507767B2 (en)	2001-02-08	2009-03-24	Schering Corporation	Cannabinoid receptor ligands
US7067539B2 (en) *	2001-02-08	2006-06-27	Schering Corporation	Cannabinoid receptor ligands
JP2005509032A (ja)	2001-11-14	2005-04-07	シェーリング　コーポレイション	カンナビノイドレセプターリガンド
EP1314733A1 (en) *	2001-11-22	2003-05-28	Aventis Pharma Deutschland GmbH	Indole-2-carboxamides as factor Xa inhibitors
WO2006044645A2 (en) *	2004-10-13	2006-04-27	Adolor Corporation	Sulfamoyl benzamides and methods of their use

2002
- 2002-11-12 JP JP2003544011A patent/JP2005509032A/ja active Pending
- 2002-11-12 NZ NZ532291A patent/NZ532291A/en unknown
- 2002-11-12 WO PCT/US2002/036185 patent/WO2003042174A1/en active IP Right Grant
- 2002-11-12 CN CNB028226755A patent/CN100567266C/zh not_active Expired - Fee Related
- 2002-11-12 MX MXPA04004674A patent/MXPA04004674A/es unknown
- 2002-11-12 EP EP02784433A patent/EP1444203A1/en not_active Withdrawn
- 2002-11-12 CA CA002466440A patent/CA2466440A1/en not_active Abandoned
- 2002-11-12 IL IL16143902A patent/IL161439A0/xx unknown
- 2002-11-12 PL PL02369952A patent/PL369952A1/xx not_active Application Discontinuation
- 2002-11-12 RU RU2004117907/04A patent/RU2004117907A/ru not_active Application Discontinuation
- 2002-11-12 KR KR1020047007188A patent/KR20050044417A/ko not_active Withdrawn
- 2002-11-12 HU HU0401924A patent/HUP0401924A3/hu unknown
- 2002-11-12 AR ARP020104334A patent/AR037352A1/es unknown
- 2002-11-12 BR BR0214164-7A patent/BR0214164A/pt not_active IP Right Cessation
- 2002-11-12 TW TW091133142A patent/TW200302088A/zh unknown
- 2002-11-12 CN CN200910207711A patent/CN101684091A/zh active Pending
- 2002-11-12 US US10/292,778 patent/US7071213B2/en not_active Expired - Fee Related
- 2002-11-13 PE PE2002001100A patent/PE20030720A1/es not_active Application Discontinuation
2004
- 2004-05-12 EC EC2004005104A patent/ECSP045104A/es unknown
- 2004-05-13 ZA ZA200403685A patent/ZA200403685B/en unknown
- 2004-06-11 NO NO20042435A patent/NO20042435L/no unknown
2005
- 2005-08-05 US US11/197,979 patent/US7645774B2/en not_active Expired - Fee Related
2009
- 2009-10-26 JP JP2009245983A patent/JP2010018635A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JP2005509032A (ja)	2005-04-07
US20040010013A1 (en)	2004-01-15
JP2010018635A (ja)	2010-01-28
HUP0401924A3 (en)	2009-07-28
IL161439A0 (en)	2004-09-27
TW200302088A (en)	2003-08-01
CN1585749A (zh)	2005-02-23
RU2004117907A (ru)	2006-01-10
US20050282861A1 (en)	2005-12-22
CN101684091A (zh)	2010-03-31
PL369952A1 (en)	2005-05-02
EP1444203A1 (en)	2004-08-11
CA2466440A1 (en)	2003-05-22
HUP0401924A2 (hu)	2005-01-28
ECSP045104A (es)	2004-06-28
CN100567266C (zh)	2009-12-09
NZ532291A (en)	2005-11-25
KR20050044417A (ko)	2005-05-12
WO2003042174A1 (en)	2003-05-22
PE20030720A1 (es)	2003-08-29
US7645774B2 (en)	2010-01-12
US7071213B2 (en)	2006-07-04
NO20042435L (no)	2004-06-11
BR0214164A (pt)	2004-09-28
AR037352A1 (es)	2004-11-03
MXPA04004674A (es)	2004-08-12

Publication	Publication Date	Title
ZA200403685B (en)	2005-05-23	Cannabinoid receptor ligands.
WO2022222994A1 (zh)	2022-10-27	一种核苷类化合物及其在治疗猫传染性腹膜炎中的应用
JP2024059874A (ja)	2024-05-01	ＳＨＰ２のオクタヒドロシクロペンタ［ｃ］ピロールのアロステリック阻害剤
JP2021534124A (ja)	2021-12-09	癌治療用ｐｔｐｎ１１（ｓｈｐ２）阻害剤としての６−（４−アミノ−３−メチル−２−オキサ−８−アザスピロ［４．５］デカン−８−イル）−３−（２，３−ジクロロフェニル）−２−メチルピリミジン−４（３ｈ）−オン誘導体及び関連化合物
CN103121996B (zh)	2015-10-21	用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物
DK2152692T3 (en)	2016-09-26	EXTERNAL anti-cancer activity
WO2020259432A1 (zh)	2020-12-30	Kras-g12c抑制剂
KR20220066923A (ko)	2022-05-24	Shp2 포스파테이스 억제제 및 이의 제조 및 사용 방법
JP6380777B2 (ja)	2018-08-29	ＰＩ３Ｋ、ｍＴＯＲ阻害薬としての縮合キノリン化合物
AU2013227024A1 (en)	2014-09-18	Novel piperidine compound or salt thereof
JP2024515140A (ja)	2024-04-04	ヌクレオシド系化合物及び猫伝染性腹膜炎の治療におけるその使用
KR20190130573A (ko)	2019-11-22	칼슘 채널 억제제
CN112062730A (zh)	2020-12-11	作为gpr139的调节剂的4-氧代-3,4-二氢-1,2,3-苯并三嗪类
ES2338060T3 (es)	2010-05-03	Componentes de tipo ariloxi y ariltoxia-cetofenona para el tratamiento del cancer.
KR20140033432A (ko)	2014-03-18	(s)-피롤리딘-1,2-디카르복실산 2-아미드 1-(｛4-메틸-5-[2-(2,2,2-트리플루오로-1,1-디메틸-에틸)-피리딘-4-일]-티아졸-2-일｝-아미드)의 다형체
EP4153175A1 (en)	2023-03-29	Piperidine-2,6-diones as small molecule degraders of helios and methods of use
WO2023227052A1 (zh)	2023-11-30	双环衍生物parp抑制剂及其用途
CN116217592A (zh)	2023-06-06	含氮的三环化合物、其制备方法及其在医药上的应用
CN115894520A (zh)	2023-04-04	一种大环k-ras g12c抑制剂及其制备方法和在药学上的应用
JP2017534572A (ja)	2017-11-24	ＣａＭＫＩＩ阻害剤及びその使用
CN115109061B (zh)	2025-01-28	三环化合物
ES2782113T3 (es)	2020-09-10	Compuestos de quinolina fusionados como inhibidores de PI3K/mTor
JP6927959B2 (ja)	2021-09-01	ベンジリデングアニジン誘導体と化学療法剤の併用による癌の治療方法
WO2020064004A1 (zh)	2020-04-02	一种mdm2抑制剂，及其制备方法、药物组合物和应用
CN104302294A (zh)	2015-01-21	用于治疗淋巴组织增生性恶性肿瘤的作为磷脂酰肌醇3-激酶抑制剂的n-(3-{[(3-{[2-氯-5-(甲氧基)苯基]氨基}喹喔啉-2-基)氨基]磺酰基}苯基)-2-甲基丙氨酰胺